Adenylyl cyclase 1 as a Therapy Target for Ethanol-Induced Neuroplastic Deficits

NIH RePORTER · VA · IK2 · · view on reporter.nih.gov ↗

Abstract

 DESCRIPTION: The application is a third submission of a CDA-2 that has been reviewed by a VA review panel twice before. The previous application was reviewed favorably with the majority of the negative comments being related to the mentoring program. In addition, there were some small comments related to the specificity of the effect and the region of the brain to be studied and the use of pharmacological inhibitors. The author has responded very strongly scientifically by adding figures 8 and 14 to the revised proposal where she shows that ethanol intake is significantly decreased in the AC1 inhibitor group. I think this is a thorough response to the scientific portion. Regarding mentoring, the applicant has provided more information regarding the productivity, seniority and the training to be provided by Dr. Conti. In my opinion, this response was less convincing. My overall level of enthusiasm is only moderate.

Key facts

NIH application ID
9795376
Project number
5IK2RX001623-05
Recipient
JOHN D DINGELL VA MEDICAL CENTER
Principal Investigator
Kelly Bosse
Activity code
IK2
Funding institute
VA
Fiscal year
2020
Award amount
Award type
5
Project period
2015-11-01 → 2021-10-31